Axial Spondyloarthropathies in the Western Cape by Smith, Robert
1	
AXIAL SPONDYLOARTHROPATHIES IN THE WESTERN CAPE 
Dr. Robert Smith 
SMTROB013 
Masters in Medicine 
University of Cape Town 
Supervisors: 
Prof. Bridget Hodkinson: Division of Rheumatology, Department of Medicine, 
University of Cape Town and Groote Schuur Hospital. 
Dr. Trevor Gould: Department of Medicine, University of Cape Town and 
George Regional Hospital. 
This thesis is submitted as a publication-ready manuscript with a literature review 
and a manuscript. 
Un
ive
rsi
ty 
of 
Ca
pe
To
wn
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
	 2	
CONTENTS 
 
 Pg: 
List of tables and figures 3 
Declaration 4 
Abstract 5-6 
Acknowledgements and contributions 7 
Introduction and Literature Review 8-18 
Publication-ready Manuscript  
Title Page 19-20 
Manuscript 21-32 
Appendix  
A) Informed Consent form (English) 33-35 
B) Data collection sheet 36-37 
C) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 38 
D) Bath Ankylosing Spondylitis Functional Index (BASFI) 39 
E) Bath Ankylosing Spondylitis Global score (BAS-G) 39 
F) Work productivity and Activity Impairment Questionnaire 
(WPAI:SHP) 
40-41 
G) Medical Short Form (SF)-36 42-44 
H) Rheumatology International Instruction to Authors 45-50 
I) Ethics Approval 51 
  
	 3	
LIST OF TABLES AND FIGURES 
 
 Title: Pg: 
 Introduction and Literature review:  
Figure 1 The 1984 Modified New York Classification Criteria for the 
diagnosis of Ankylosing Spondylitis 
9 
Figure 2 ASAS Classification Criteria for Axial Spondyloarthritis 10 
 Manuscript:  
Table 1 Demographic and clinical features of 36 patients with Axial 
Spondyloarthritis, including subgroups with high disease activity 
(BASDAI score ≥ 4) compared to low disease activity (BASDAI 
score < 4) 
30 
Figure 1 Radar graph representing SF-36 subscales of Axial Spondyloarthritis 
patients and healthy controls 
31 
Table 2 Pearson correlation coefficients showing negative linear correlations 
between BASDAI, BASFI, BAS-G and domains of the SF-36 
32 
 
  
4	
DECLARATION PAGE 
The research presented here is based on independent work performed by the primary 
investigator, Dr. Robert B. Smith. No part of this work has, or will be, submitted for 
another degree to any other university. This research has not been reported or published 
prior to registration for the above-mentioned degree. I empower the university to 
reproduce for the purpose of research either the whole or any portion of the contents in 
any manner whatsoever. 
Dr. Robert B Smith 
Date: 21 November 2018 
	 5	
ABSTRACT 
 
Impaired Health-Related Quality of Life and Work Productivity amongst South African 
patients with Axial Spondyloarthritis. 
 
Background: 
No studies have investigated health-related quality of life (HRQoL) or work 
productivity in patients with axial spondyloarthritides (axSpA) living in sub-Saharan 
Africa. 
 
Methods: 
This cross-sectional study of adults with axSpA collated demographic particulars and 
patient questionnaires: Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI); Bath Ankylosing Spondylitis Functional Index (BASFI); Bath Ankylosing 
Spondylitis Global Score (BASG); Medical Short Form (SF)-36; and Work 
Productivity and Activity Impairment Questionnaire: Specific Health Problem 
(WPAI:SHP). 
 
Results: 
Of 36 patients, the mean (SD) age was 40.3 (13.3) years and mean (SD) diagnostic 
delay was 8.7 (8.4) years. Most patients were male (80.6%) and of mixed racial ancestry 
(69.4%). Most (66.7%) patients were smokers and only 5 (13.9%) patients received 
tumor necrosis factor inhibitor (TNFi) therapy. The mean (SD) BASDAI was 5.3 (2.1), 
and 72.2% had a BASDAI ≥ 4. Patients with a high BASDAI (i.e. BASDAI ≥ 4) had 
higher BASG scores (p=0.003), higher WPAI:SHP activity impairment scores 
(p=0.003), and poorer SF-36 scores, particularly in the role-physical, bodily pain, and 
social functioning domains (p=0.0001, 0.001 and 0.02 respectively). Activity 
impairment according to the WPAI:SPH was 57.4%, with the BASDAI and activity 
impairment correlating closely (p=0.006). The SF-36 scores were low in physical 
(particularly role-physical, bodily pain, and general health) and mental (notably vitality 
and role emotional) domains. 
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Conclusion: 
This study describes a cohort of South African patients with axSpA who have poor 
prognostic features including diagnostic delay and cigarette smoking. Active disease, 
impaired function, poor physical- and mental HRQoL, and work disability are unmet 
needs. 
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INTRODUCTION AND LITERATURE REVIEW 
 
BACKGROUND 
The spondyloarthritides (SpA) are a family of disorders that are grouped together by 
common clinical features and an association with the human leucocyte antigen-B27 
(HLA-B27). The prototypical disorder in this family is known as ankylosing 
spondylitis, but others include are psoriatic arthritis, reactive arthritis, arthritis related 
to inflammatory bowel disease and undifferentiated arthritis [1]. A recent, revised 
classification of SpA that was proposed by the Assessment of Spondyloarthritis 
International Society (ASAS), separates the disorders into those presenting with 
predominantly axial symptoms and those presenting with predominantly peripheral 
symptoms. According to this classification, axial spondyloarthritis (axSpA) includes 
ankylosing spondylitis (AS) and non-radiographic (nr) axSpA [2-4]. 
 
In axSpA, young adults typically present with inflammatory back pain and 
progressively worsening stiffness of the spine. Other associated symptoms include 
peripheral arthritis, enthesitis (inflammation of the entheses, the tendinous or 
ligamentous insertions on bone) and dactylitis (inflammation of the digits). There are 
also numerous associated extra-articular manifestations, including uveitis, 
inflammatory bowel disease, psoriasis, cardiovascular- and pulmonary disease [1]. 
 
The course of the disease is variable. Disease progression leads to stiffness and varying 
degrees of spinal fusion, which causes marked functional impairment. Pain and 
limitation of physical function has a negative impact on health-related quality of life 
(HRQoL) [1]. This also impacts on work productivity in affected individuals. This was 
illustrated in a systematic literature review describing work status in patients with AS 
done by Boonen et al. [5]. The authors concluded that there was substantial work 
disability and sick leave. The findings were, however, limited by the marked 
heterogeneity of the patient populations that were studied, as well as of the designs of 
the various studies that were included in the analysis. In the review, employment in AS 
ranged between 34-96%, with half of the studies reporting employment of less than 
70% [5]. In addition to the physical impairment and the impact on work productivity, 
the disease also results in fatigue and psychological disturbance (depression and 
anxiety) in many. [6] 
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DIAGNOSIS 
The diagnostic delay in axSpA has been recognised in several studies, with reports of 
delays between 5 - 10 years [7-9]. As shown in Figure 1, the 1984 Modified New York 
Classification Criteria for Ankylosing Spondylitis were historically used to aid in the 
diagnosis of the disorder [10]. However, for the diagnosis of AS to be made according 
to these criteria, sacroiliitis must be present on plain film radiographs. These plain film 
radiological changes may take several years to develop, resulting in a delay in the 
diagnosis. As will be discussed later, this is of importance as early diagnosis and 
initiation of therapy may improve outcome. 
 
Figure 1: The 1984 Modified New York Criteria for the diagnosis of Ankylosing 
Spondylitis [10]. 
 
 
 
The ASAS classification criteria for axSpA attempts to address this problem. It was 
developed to diagnose patients with early axial disease, or non-radiographic axSpA (nr-
axSpA) [2-4]. These criteria are shown in Figure 2. As the name implies, patients with 
nr-axSpA lack the plain film radiographic changes to the sacroiliac joints that is 
necessary to meet the diagnosis according to the 1984 Modified New York Criteria. 
Although patients with nr-axSpA may have normal plain films, inflammation 
suggestive of sacroiliitis is visible on MRI. 
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Figure 2: ASAS classification criteria for Axial Spondyloarthritis [4]. 
 
 
 
Recently, there has been a decline in the diagnostic delay [11-12] likely due to the new 
ASAS classification criteria [3] and the recognition of nr-axSpA. 
 
In the majority of cases, the initial presenting complaint in patients with axSpA is 
inflammatory back pain (IBP). Recognising IBP is therefore an important first step in 
the diagnosis of the disorder and health care professionals should be aware of its 
characteristics. IBP should be considered in individuals younger than 40 years of age 
with insidious onset back pain for a period of more than three months. 
Characteristically, IBP improves with exercise, does not improve with rest and is 
experienced at night [13]. Rudwaleit et al. showed that in patients younger than 45 
years of age with chronic lower back pain, identifying IBP or testing for HLA-B27, 
with referral to a rheumatologist if either of these are positive, may be an approach to 
reducing the delay in diagnosing patients with axSpA [14]. 
 
ASSESSMENT OF DISEASE STATUS 
Accurate assessment of disease status in SpA is important as it guides management 
decisions. Patient completed questionnaires specific to the condition are widely used in 
daily practice to assess disease activity and functional status [15-16]. These include the 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing 
Spondylitis Functional Index (BASFI) and the Bath Ankylosing Spondylitis Global 
score (BASG), which assess disease activity, functional impairment and general health, 
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respectively. The Ankylosing Spondylitis Disease Activity Score (ASDAS) measures 
disease activity and incorporates acute phase reactants [17]. Use of the BASDAI, 
BASFI, BASG and ASDAS has been validated in AS. Another validated self-reported 
questionnaire, the Work Productivity and Activity Impairment Questionnaire: Specific 
Health Problem (WPAI:SHP), is used to assess work productivity and impairment in 
daily activities [18]. In employed individuals, the WPAI:SHP reports on absenteeism 
(sick leave related to disease), presenteeism (impairment in productivity related to 
disease) and overall impairment at work. 
 
The Medical Short Form (SF)-36 is an instrument used to measure HRQoL [19]. This 
questionnaire is not disease specific. It has been validated in numerous diseases, 
including rheumatologic diseases such as rheumatoid arthritis [20] and AS. The 
questionnaire contains 36 items that can be grouped into eight domains. Four of these 
are physical domains and four are mental domains. The physical domains are: physical 
functioning, bodily pain, role physical, and general health perceptions; whereas the 
mental domains are: vitality, role emotional, social functioning, and mental health [19]. 
A meta-analysis was conducted by Yang et al. [21] to evaluate the impact of AS on the 
HRQoL as assessed by the Medical SF-36 questionnaire. The authors concluded that 
the measurement of HRQoL using the SF-36 should be considered as an essential part 
of the overall assessment of health status of patients with AS. Importantly, it guides 
improved management. Of note, none of the studies included in the meta-analysis were 
conducted in South Africa [21]. The above-mentioned questionnaires are included in 
the appendix (Appendix C-G). 	
MANAGEMENT 
The optimal management of axSpA requires a combination of treatment modalities, 
both non-pharmacological and pharmacological [22-23]. Non-pharmacological 
management refers to patient education, smoking cessation and exercise. Exercise has 
been shown to be of benefit, whether it is individual home-based exercise or supervised 
group therapy [24-25]. The first line of pharmacotherapy for all patients is non-steroidal 
anti-inflammatory drugs (NSAIDs), and in many patients it may be the only medication 
required [26]. The current recommendations for the use of NSAIDs are that, in the 
absence of contra-indications or side-effects, they should be used at the maximum dose 
in a continuous manner for patients with active disease [23]. In patients with 
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persistently high disease activity despite an adequate trial of 4 weeks of NSAIDs, a 
biological disease modifying anti-rheumatic drug (bDMARD) is considered [23]. The 
tumor necrosis factor inhibitors (TNFi) have been associated with significant 
improvements in disease activity and function [27]. The highest remission rates are 
observed when used in patients with early disease, therefore earlier diagnosis improves 
outcome [28-29]. The non-biological, or conventional synthetic DMARDs often used 
include sulfasalazine and methotrexate. In patients with peripheral arthritis, 
sulfasalazine has been shown to be of benefit. Use of sulfasalazine, however, is not 
recommended in the absence of peripheral arthritis [30]. Although it is widely used, a 
meta-analysis evaluating the efficacy of methotrexate in AS found no evidence of 
benefit for its use in this disease [31]. 
 
PROGNOSTIC INDICATORS 
Various factors are associated with poor outcomes in patients with axSpA. These 
include age, male sex, cigarette smoking, a history of uveitis, lower educational level, 
presence of other diseases related to SpA, presence of HLA-B27, active disease as 
assessed by a disease activity index, self-reported functional impairment, the presence 
of enthesitis, increasing severity of radiographic changes and elevated C-reactive 
protein (CRP) [32-34]. Elevated CRP levels, baseline severity of radiographic change 
and cigarette smoking are associated with increased risk of radiographic progression 
[35-36]. 
 
AXIAL SPONDYLOARTHRITIDES IN SUB-SAHARAN AFRICA 
SpA is uncommon in sub-Saharan Africa. Dean et al. reported the mean prevalence of 
AS in Africa at 7.4 per 10000 [37]. This estimate was based on a single cross-sectional 
study of 1352 persons conducted in South Africa [37]. In comparison, the mean 
prevalence per 10000 in Europe, Asia, North America and Latin America is 23.8, 16.7, 
31.9 and 10.2, respectively [37]. The reason for the low prevalence in Sub-Saharan 
Africa is likely due to the low frequency of HLA-B27 in the African Black population 
[39]. Studies done in Togo, Zambia and Burkino Faso, have identified other HLA 
alleles, namely HLA-B 14:03 and HLA-B 27:05, to be associated with an increased risk 
for the development of axSpA in sub-Saharan African populations [40]. 
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There are numerous challenges to the diagnosis and treatment of the SpA in sub-
Saharan Africa. The diagnosis is often delayed until late in the course of the disease. 
Various reasons may include low public awareness resulting in late presentation, 
inadequate health care service access by the general population, lack of health care 
professionals with rheumatology skills to recognise the condition early, and limited 
access to specialised investigations. Furthermore, there is doubt as to whether the new 
ASAS classification criteria will be of clinical value in sub-Saharan Africa, due to the 
rarity of HLA-B27 and the limited access to magnetic resonance imaging (MRI) [39]. 
Once the diagnosis is made, treatment is mostly limited to exercise and NSAIDs. TNFi 
agents are not only prohibitively expensive, but exposure to these agents has been 
shown to be an independent risk factor for tuberculosis (TB) in high burden areas [41]. 
There are also concerns with regards to safety in the setting of human 
immunodeficiency virus (HIV) infection [42]. A cross-sectional study from Zambia 
showed 98% of SpA cases were HIV associated rather than HLA-B27 associated [43]. 
 
Few studies have investigated the characteristics of patients living with axSpA in South 
Africa. A retrospective survey of 100 patients with AS seen between January 1988 and 
January 1995 at the Rheumatic Diseases Unit of the University of Cape Town, 
concluded that the spectrum of SpA in South Africa is comparable to that found in other 
parts of the world [44]. A more recent cross-sectional study in Kwazulu-Natal described 
the ethnicity of 248 patients with AS. It was found in this cohort that 74% of patients 
were White, 26% were Indian, and that there were no Black patients [45]. No study in 
South Africa has described the HIV- and HLA-B27 associations, or the disease status, 
HRQoL and work productivity of patients with axSpA. 
 
OBJECTIVES 
The objective of this cross-sectional study is to investigate a cohort of consenting adults 
with axSpA residing in the Western Cape, South Africa. 
Firstly, the following will be described: 
1. The demographics and characteristics of the group, including age, gender and 
self-reported ethnicity; 
2. The disease history, including presenting symptom(s), age at symptom onset, 
symptom duration and diagnostic delay; 
3. Employment history; 
	 14	
4. The association with HLA B-27 and HIV infection, when available; 
5. The poor prognostic indicators identified; and 
6. Treatment exposure, side-effects and response. 
Following this, the disease activity, functional impairment, work productivity and 
health related quality of life will be determined using the validated, self-reported 
questionnaires that were discussed under the heading Assessment of Disease Status 
above. Together, the information gathered will provide insight on the challenges 
involved in the diagnosis and management of patients with axSpA in South Africa, and 
will be the first to report on work productivity and HRQoL in this setting. 
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Manuscript: 
 
Impaired Health-Related Quality of Life and Work Productivity amongst South 
African patients with Axial Spondyloarthritis 
 
Background 
Axial Spondyloarthritides (axSpA) are chronic inflammatory disorders primarily 
affecting the axial skeleton in young adults, typically presenting with inflammatory 
back pain. Disease progression may result in spinal fusion. Other features of axSpA 
include peripheral arthritis, enthesitis and dactylitis, together with extra-articular 
complications, such as uveitis, inflammatory bowel disease, psoriasis, cardiovascular 
and pulmonary disease [1]. Untreated disease may lead to functional impairment, poor 
health-related quality of life (HRQoL) and impaired work productivity [2-4]. 
 
There are numerous challenges to the diagnosis and treatment of axSpA in sub-Saharan 
Africa. These diseases are somewhat uncommon, and have been described as mild in 
the African population, attributed to the low frequency of the HLA-B27 gene [5-6]. The 
diagnosis is often delayed until late in the course of the disease. Reasons for this include 
low public awareness and inadequate training of health care professionals to recognise 
the condition, together with limited access to specialised investigations such as 
magnetic resonance imaging (MRI) [7]. The Assessment of Spondyloarthritis 
International Society (ASAS) classification criteria for axSpA were developed to aid in 
the diagnosis of patients with early axial disease, but these may be of limited clinical 
value in sub-Saharan Africa, due to the rarity of HLA-B27 and the limited access to 
MRI [8]. Once the diagnosis of axSpA is made, treatment includes exercise and non-
steroidal anti-inflammatory drugs (NSAIDs). Biologic disease modifying anti-
rheumatic (bDMARD) agents, including tumour necrosis factor inhibitors (TNFi) are 
prohibitively expensive and therefore not widely available in resource-constrained 
settings such as ours, and also infer a significant risk of tuberculosis (TB) which is of 
major concern in TB endemic regions such as South Africa (SA) [9]. 
 
There are few papers published on axSpA from sub-Saharan Africa, and none have 
investigated HRQoL. We undertook this study to investigate clinical features, HRQoL 
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including function and work productivity in a cohort of axSpA patients from the 
Western Cape, SA.  
 
Patients and methods 
A cross-sectional study of consenting adult patients (≥ 18 years of age) with a diagnosis 
of axSpA according to the ASAS classification criteria were enrolled from the 
outpatient departments of a regional and a tertiary academic hospital. The University 
of Cape Town Human Research Ethics Committee approved the study, and all 
participants signed informed consent. 
 
Demographic information including self-reported ethnic background, HLA-B27, HIV 
status and C-reactive protein (CRP) level were documented, where available. Disease 
status was assessed using patient completed questionnaires, namely: Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI); Bath Ankylosing Spondylitis 
Functional Index (BASFI); and Bath Ankylosing Spondylitis Global score (BASG). 
The Medical Short Form (SF)-36 was used to assess HRQoL [10-12]. Thirty age- and 
sex-matched healthy controls completed the Medical SF-36 questionnaire. The Work 
Productivity and Activity Impairment Questionnaire: Specific Health Problem 
(WPAI:SHP) was used to assess work and home productivity [13]. 
 
Statistical analysis was performed using data analysis software in Microsoft Excel. 
Pearson correlation coefficients were calculated to show relationship between 
variables. The Students t-test was applied to compare continuous variables, and in the 
case of categorical variables, the Pearson’s Chi-Square test, or where indicated, the 2-
tailed Fishers’ Exact test was used. A p value < 0.05 was considered significant. 
 
Results 
Of 36 patients, the mean (SD) age was 40.3 (13.3) years and symptom duration was 
16.8 (11.2) years (Table 1). Most patients were male (80.6%) and of mixed racial 
ancestry (69.4%). There were only 2 (5.6%) black African patients. There was 
significant diagnostic delay, with a mean (SD) lag between symptom onset to disease 
diagnosis of 8.7 (8.4) years. Patients had a poor socio-economic background: all were 
attending state-sector hospitals, none had medical insurance, and more than half 
(58.3%) were unemployed. 
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The majority of patients presented with lower back pain without peripheral arthritis 
(55.6%), followed by lower back pain and peripheral arthritis (30.6%), and the minority 
with peripheral arthritis alone (13.9%). Fourteen (38.9%) patients had a history of 
uveitis, and enthesitis was documented in 6 (16.7%) patients. All the patients fulfilled 
the ASAS classification criteria for ankylosing spondylitis, and none had psoriasis, 
inflammatory bowel disease or reactive arthritis. Most (66.7%) patients were cigarette 
smokers with a mean (SD) pack year smoking duration of 14.9 (16.8) years. HLA-B27 
was positive in 25 of 27 (92.6%) patients tested, and 9 (25.0%) patients reported a 
family history. The HIV status was unknown in 20 (55.6%) patients, and of the 16 
patients tested, none were HIV positive. Nine (25.0%) patients had a history of 
pulmonary TB. 	
Disease Activity 
The mean (SD) BASDAI was 5.3 (2.1) and the mean (SD) BASG was 6.4 (2.3). Most 
(72.2%) patients had a BASDAI ≥ 4. The mean (SD) CRP at the time of the study was 
16.5 (18.2) g/L, and 71.4% had a CRP ³ 6 g/L. Plain X-rays, scored according to the 
modified New York grading for sacroiliitis [14], showed grade 4 sacroiliitis in 23.1% 
of those available. Three patients had undergone hip arthroplasty (unilateral = 1; 
bilateral = 2). An MRI had been performed in 7 patients (19.4%) and confirmed 
sacroiliitis in all. 
 
Therapy 
Most (80.6%) patients used NSAIDs (alone = 17.2%; combination with other agents = 
82.8%), and the majority (79.3%) reported an improvement in symptoms. However, 11 
(37.9%) had a history of upper gastrointestinal symptoms suggestive of gastritis. 
Sulfasalazine was prescribed to 24 (66.7%) patients, although only 12 (50.0%) of these 
patients reported peripheral arthritis. Methotrexate was prescribed to 4 (11.1%) 
patients, and TNFi therapy to 5 (13.9%) patients. Only 8 (22.2%) patients practiced 
regular home-based exercise. 
 
Functional impairment, health related quality of life and employment 
The mean (SD) BASFI was 5.8 (2.6) and activity impairment according to the 
WPAI:SPH was 57.4%. All domains of the SF-36 were markedly impaired compared 
to healthy controls (Figure 1). The mean (SD) SF-36 physical composite score (PCS) 
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was 39.5 (18.9), with particularly low scores in role-physical, bodily pain and general 
health. The mean mental composite score (MCS) was 50.0 (18.5), with vitality and role 
emotional most affected. 
 
Twenty-one (58.3%) patients were unemployed, and of these, 12 (57.1%) related 
unemployment to the impact of the disease on their ability to work. The scores obtained 
from WPAI:SHP for employed patients were as follows: 6.3% for absenteeism 
(percentage of work time missed related to the disease), 49.7% for presenteeism 
(percentage impairment whilst working related to the disease) and 45.7% for overall 
work impairment. The SF-36 scores were lower in the patients who could not work due 
to their disease, however the differences were not statistically significant. The role-
emotional and mental health domains approached significance (p=0.08 and 0.06 
respectively). 
 
Variables associated with high disease activity 
Comparing patients with high disease activity (BASDAI ≥ 4) with those with low 
disease activity (BASDAI < 4), there were no significant differences in demographic 
features (Table 1). High disease activity was associated with higher BASG scores 
(p=0.003), higher WPAI:SHP activity impairment scores (p=0.004), a BASFI that 
approached significance (p=0.06) and poorer SF-36 scores, particularly in the role-
physical, bodily pain, and social functioning domains (p=0.005, 0.001 and 0.02 
respectively). 
 
Correlations 
There were statistically significant negative linear correlations between the BASDAI, 
BASFI, BAS-G and the certain domains of the SF-36 (Table 2). The strongest of these 
correlations were found between BASDAI and bodily pain, BASFI and bodily pain, 
and BASFI and general health. The was a strong positive linear correlation between the 
BASDAI and activity impairment according to the WPAI:SPH (R 0.64; p=0.006). 
Linear correlations were not demonstrated between age, symptoms duration, diagnostic 
delay and the BASDAI, BASFI or BASG, respectively. 
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Discussion 
This study, the first to focus on HRQoL amongst axSpA patients in sub-Saharan Africa, 
demonstrates considerable disease activity, functional disability and poor physical and 
mental health scores accompanied by reduced productivity. As expected, disease 
activity was significantly associated with these impairments. Diagnosis was late in the 
disease course, radiographic changes were advanced, several patients had undergone 
hip arthroplasty and a high percentage of our patients were cigarette smokers. Thus, 
several factors associated with poor prognosis and radiographic progression of disease 
were present [15-17]. 
 
The patient characteristics were similar to those described in the literature from SA and 
elsewhere with regards to presenting symptoms, age of symptom onset, male 
predominance and HLA-B27 association [18]. Most patients were of mixed racial 
ancestry and only two patients were blacks Africans, perhaps reflecting a true low 
prevalence of axSpA in this population. Although there are reports from Africa of 
spondyloarthritides associated with HIV infection, no HIV infected individuals were 
identified in this study [19]. 
 
There was a marked delay between onset of symptoms and diagnosis of disease. This 
diagnostic delay has been recognised in other studies, where delays of 5 - 10 years are 
reported [17,20]. Recently, this delay has declined, likely due to the new ASAS 
classification criteria and the recognition of non-radiographic axSpA [21-22]. Since the 
introduction of TNFi in the treatment of axSpA, early diagnosis is becoming 
increasingly important, as its use has been shown to have a greater impact in patients 
with early disease [23]. It is therefore important for health care professionals to be 
aware of the characteristics of inflammatory back pain. 
 
The optimal management of patients with axSpA is a combination of non-
pharmacological and pharmacological treatment [24]. In our cohort, few patients made 
use of non-pharmacological modalities, and despite high disease activity, less than half 
of the patients used NSAIDs continuously. Very few patients were prescribed TNFi 
because of resource constraints, and concern of infection, particularly TB in this 
endemic area [25]. Indeed, a quarter of our patients reported a history of TB. There is 
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an urgent need for wider access to biologic therapies for these patients, but vigilance is 
required [26]. 
 
The worst preforming domains of the SF-36 were the physical domains of role-
physical, bodily pain and general health, findings similar to those reported in a 
systematic review of HRQoL assessed in AS patients [4]. Besides poor performance in 
the physical domains, our patients had impairment in mental domains, in particular role-
emotional and vitality. In keeping with this, depression and fatigue are emerging as 
major under-recognised burdens in SpA [27-28]. 
 
Functional impairment has a negative effect on employment and work performance. A 
systematic literature review concluded that work disability and sick leave in AS was 
substantial [2].  In our cohort, more than half of the unemployed patients related this to 
the impact of the disease on their ability to work, and of those who were employed, a 
significant impairment whilst working was demonstrated.  
 
This study has limitations, including the small sample size, and missing data, in 
particular CRP level, HIV- and HLA-B27 status for some participants. We plan to 
enlarge this cohort and broaden our investigations with qualitative and interventional 
studies. 
 
In conclusion, this study describes a cohort of SA patients with axSpA who have poor 
prognostic features, active disease, impaired function, poor HRQoL and work 
disability. Strategies to improve these outcomes might include better awareness and 
early referral of patients with inflammatory back pain, interventions to encourage 
smoking cessation, exercise, job retention and improved mental health together with 
improved access to biologic therapies. 
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Table 1: Demographic and clinical features of 36 patients with Axial Spondyloarthritis, 
including subgroups with high disease activity (BASDAI score ≥ 4) compared to low 
disease activity (BASDAI score < 4) 
 
 n=36 BASDAI ≥ 
4; n=26 
BASDAI < 
4; n=10 
p 
Age - yr; mean (SD) 40.3 (13.3) 39.7 (13.4) 41.9 (13.6) ns 
Age at symptom onset - yr; mean (SD) 24.1 (9.1) 23.7 (8.4) 25.3 (11.2) ns 
Symptom duration - yr; mean (SD) 16.8 (11.2) 16.7 (12.3) 17.0 (7.7) ns 
Diagnostic delay - yr; mean (SD) 8.7 (8.4) 7.9 (7.8) 11.1 (10.1) ns 
Male - no. (%) 29 (80.6) 20 (76.9) 10 (90.9) ns 
Mixed Ancestry - no. (%) 25 (69.4)  20 (76.9)  5 (50.0)  ns 
Caucasian - no. (%) 9 (24.3) 4 (15.4) 5 (50.0)  ns 
Black - no. (%) 2 (5.6) 2 (7.7) 0 ns 
Unemployed - no. (%) 21 (58.3) 14 (53.8) 7 (70.0) ns 
Cigarette smoking ever - no. (%) 24 (66.7)  17 (65.4) 7 (70.0) ns 
Pack years of smoking - yr; mean (SD) 14.9 (16.8) 9.6 (5.8) 27.8 (26.9) ns 
CRP - mg/l, mean (SD) 16.5 (18.2) 16.7 (19.2) 15.7 (17.6) ns 
BASDAI - mean (SD) 5.3 (2.1) 6.3 (1.3) 2.6 (1.1) <0.001 
BASFI - mean (SD) 5.8 (2.6) 6.4 (2.1) 4.4 (3.4) 0.06 
BASG - mean (SD) 6.4 (2.3) 7.3 (1.4) 4.2 (2.7) 0.003 
Physical functioning - mean (SD) 50.4 (24.9) 48.7 (21.8) 55.0 (32.6) ns 
Role physical - mean (SD) 30.6 (39.7) 18.3 (32.1) 62.5 (41.2) 0.0001 
Bodily pain - mean (SD) 35.9 (21.8) 29.5 (16.4) 52.6 (25.8) 0.001 
General health - mean (SD) 36.1 (15.9) 33.3 (13.2) 43.5 (20.5) ns 
Vitality - mean (SD) 44.4 (21.2) 41.5 (21.0) 52.0 (20.8) ns 
Social functioning - mean (SD) 60.1 (21.3) 55.3 (20.4) 72.5 (19.4) 0.02 
Role emotional - mean (SD) 43.5 (43.5) 35.9 (42.1) 63.3 (42.9) ns 
Mental health - mean (SD) 65.7 (19.5) 64.3 (19.4) 69.2 (20.3) ns 
PCS - mean (SD) 39.5 (18.9) 34.2 (14.3) 53.1 (23.2) 0.02 
MCS - mean (SD) 50.0 (18.5) 46.1 (16.1) 60.1 (21.3) 0.04 
WPAI activity impairment - mean (SD) 57.4 (24.3) 66.8 (14.9) 27.5 (27.8) 0.003 
 
Abbreviations: BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BAS-G: Bath 
Ankylosing Spondylitis Global Score; CRP: C-reactive protein; ns: not significant; MCS: Mental Composite Score; PCS: Physical Composite Score; WPAI: 
Work Productivity and Activity Impairment. 
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Figure 1: Radar graph representing SF-36 subscales of Axial Spondyloarthritis patients 
and healthy controls 
 
 
 
Fig. 1 A radar graph, or ‘spidergram,’ representing the various subscales of the SF-36 
compared to healthy controls. There is marked limitation in both the physical and 
mental domains of patients with axSpA. 
  
0,0
20,0
40,0
60,0
80,0
100,0
Physical functioning
Role physical
Bodily pain
General health
Vitality
Social functioning
Role emotional
Mental health
AxSpA Controls
	 32	
Table 2: Pearson correlation coefficients showing negative linear correlations between 
BASDAI, BASFI, BAS-G and domains of the SF-36 
 
  R p 
BASDAI: 
  
Bodily pain -0,5 0,001 
Role physical -0,5 0,005 
BASFI:   
Bodily pain -0,5 0,001 
General health -0,5 0,002 
BAS-G:   
Role physical -0,5 0,002 
Physical functioning -0,5 0,004 
General health -0,4 0,008 
 
Abbreviations: BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BAS-G: Bath 
Ankylosing Spondylitis Global Score. 
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APPENDICES 
 
A) INFORMED CONSENT FORM (ENGLISH) 
 
Title: 
Health related quality of life and work productivity amongst patients with axial 
spondyloarthritis living in the Western Cape 
 
Investigators: 
Dr. Robert Smith, Dr. Bridget Hodkinson and Dr. Trevor Gould. 
 
Invitation: 
You are invited to take part in a study being done by doctors from George Regional 
Hospital and Groote Schuur Hospital. 
 
Background: 
You have been chosen for this study because you are being treated for axial 
spondyloarthritis. Also known as ankylosing spondylitis, it is a troublesome disease 
that affects the spine and a number of other joints and organs in the body. Very little is 
known about the illness in South Africa and how well we are treating it with the 
medicine we have available. 
 
Study procedure: 
The study will be done when you come for your follow-up visit at the clinic. If you 
agree, we will first look your records to check your old results. You will then be asked 
to do 4 lists of questions that have been put together to measure how active your disease 
is and how badly it is affecting your life and work. You must try to answer the questions 
honestly. It will probably take 20 minutes of your time to do the questions. 
 
Confidentiality of collected information: 
Your privacy is very important to us and safety measures will be in place to protect this. 
Your information will be labeled with a code and stored in a safe place. Only doctors 
working on this study will be able to see your information. Your name will not appear 
in any reports on this study. 
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Nature of participation: 
It is important to understand that whether you want to take part in this study is your 
own choice, and you may decide to change your mind and leave the study at any stage. 
This will not be held against you. 
 
Purpose: 
What we learn from the study may help us to better understand the disease in South 
Africa. It may also help us argue for better medicine to treat the disease. 
 
Remuneration: 
You will not receive any payment for taking part in this study. 
 
Questions: 
If you have any questions relating to the study please feel free to contact: 
 
Dr. Robert Smith (Principal Researcher) 
Telephone:  (044) 802 4529; ext. 2534 
Email:  robert.smith@westerncape.gov.za 
 
University of Cape Town, Faculty of Health Sciences and Human Research Ethics 
Committee can be contacted at (021) 406 6338, if participants have any questions 
regarding their rights and welfare as research participants. 
 
By signing below, I agree that: 
I have read the information presented in the consent form; 
I have asked that anything that is unclear to me be explained, and that this was done to 
my satisfaction in a language I understand; 
I have been given the necessary time to think about whether I would like to participate 
in this study; 
I understand that participation is voluntary and consent may be withdrawn at any time. 
 
_____________________________________________________________________ 
Participant (print name)    Signature   Date 
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_____________________________________________________________________ 
Interviewers (print name)    Signature   Date 
 
_____________________________________________________________________ 
Witness (print name)     Signature   Date 
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B) DATA CAPTURE SHEET 
 
 
 
Data Capture Sheet
Date of assessment (YY/MM/DD):
Demographics
Date of birth (YY/MM/DD):
Ethnicity:
Black
White
Coloured
Asian
Employment history:
Employed Yes No
If 'No' - related to illness? Yes No
Medical background
HIV Yes No
If 'Yes' - Most recent CD4
Date (YY/MM/DD)
Anti-retroviral therapy Yes No
History of tuberculosis Yes No
Smoking Yes No
If 'Yes' - estimated pack years
Family history of SpA Yes No
Diagnosis
Date of symptom onset (YY/MM/DD)
Date of diagnosis (YY/MM/DD)
Presenting symptoms
Inflammatory lower back pain
Peripheral arthritis
Enthesitis
Extra-articular manifestations
Other
Specify?
Extra-articular manifestations
Uveitis
Inflammatory bowel disease
Psoriasis
Cardiovascular disease
Pulmonary disease
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Other
Specify?
Investigations
HLA-B27 status Pos Neg Unknown
Acute phase reactants:
CRP
Most recent value?
Value at diagnosis?
ESR
Most recent value?
Value at diagnosis?
Full blood count
Most recent? (WCC / Hb / MCV / platelets)
At diagnosis? (WCC / Hb / MCV / platelets)
Radiology:
Sacroiliitis on plain film
Grade?
Sacroillitis on MRI Yes No Not done
Disease activity and functional impairment scores
BASDAI
BASFI
SF 36
WPAI:SpA
BAS-G
Treatment
Home exercise Yes No
Physiotherapy Yes No
Analgesics Yes No
NSAIDs Yes No
Continuous? Intermittent?
Response? Yes No
Related gastritis? Yes No
Anti-TNFs Yes No
Other Yes No
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C) BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX 
(BASDAI) 
 
1. How would you describe the overall level of fatigue/tiredness you have 
experienced? 
2. How would you describe the overall level of AS neck, back or hip pain you have 
had? 
3. How would you describe the overall level of pain/swelling in joints other than neck, 
back or hips you have had? 
4. How would you describe the overall level of discomfort you have had from any 
areas tender to touch or pressure? 
5. How would you describe the overall level of discomfort you have had from the time 
you wake up?  
6. How long does your morning stiffness last from the time you wake up? 
 
(Calculation: Score of 1 - 10 (1 = none, 10 = severe) for all questions. The mean score 
of questions 5 and 6 is added to the scores from questions 1 to 4. This total is then 
divided by 5 to give the average.) 
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D) BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX (BASFI) 
 
Please indicate your level of ability with each of the following activities during the past 
week. 
 
1. Putting on your socks or tights without help or aids (e.g sock aid).  
2. Bending from the waist to pick up a pen from the floor without aid. 
3. Reaching up to a high shelf without help or aids (e.g helping hand).  
4. Getting up from an armless chair without your hands or any other help. 
5. Getting up off the floor without help from lying on your back. 
6. Standing unsupported for 10 minutes without discomfort.  
7. Climbing 12-15 steps without using a handrail or walking aid.  
8. Looking over your shoulder without turning your body. 
9. Doing physically demanding activities (e.g physiotherapy exercises, gardening or 
sports). 
10. Doing a full days activities whether it be at home or at work. 
 
(Calculation: The total is divided by 10 to give the average.) 
 
E) BATH ANKYLOSING SPONDYLITIS GLOBAL SCORE (BAS-G) 
F)  
1.  Please place a mark on the scale below to indicate the effect your disease has had 
on your well-being over the last week. 
2.  Please place a mark on the scale below to indicate the effect your disease has had 
on your well-being over the last six months. 
 
(Calculation: The total is divided by 2 to give the average.) 
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G) WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT 
QUESTIONNAIRE (WPAI:SHP) 
 
The following questions ask about the effect of your ankylosing spondylitis on your 
ability to work and perform regular activities. Please fill in the blanks or circle a 
number, as indicated. 
1. Are you currently employed (working for pay)? If no, check “No” and skip to 
question 6.         
        ___ No ___ Yes 
 
The next questions refer to the past seven days, not including today. 
2. During the past seven days, how many hours did you miss from work because 
of problems associated with your ankylosing spondylitis? Include hours you 
missed on sick days, times you went in late, left early, etc., because of your 
ankylosing spondylitis. Do not include time you missed to participate in this 
study.          
        _____ hours 
3. During the past seven days, how many hours did you miss from work because 
of any other reason, such as vacation, holidays, time off to participate in this 
study?          
        _____ hours 
4. During the past seven days, how many hours did you actually work? If “0,” 
write “0” and skip to question 6.      
        _____ hours 
5. During the past seven days, how much did your ankylosing spondylitis affect 
your productivity while you were working? Think about days you were limited 
in the amount or kind of work you could do, days you accomplished less than 
you would like, or days you could not do your work as carefully as usual. If 
ankylosing spondylitis affected your work only a little, choose a low number. 
Choose a high number if ankylosing spondylitis affected your work a great deal. 
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6. During the past seven days, how much did your PROBLEM affect your ability 
to do your regular daily activities, other than work at a job? By regular activities, 
we mean the usual activities you do, such as work around the house, shopping, 
childcare, exercising, studying, etc.  Think about times you were limited in the 
amount or kind of activities you could do and times you accomplished less than 
you would like.  If PROBLEM affected your activities only a little, choose a low 
number.  Choose a high number if PROBLEM affected your activities a great 
deal 
 
Ankylosing 
spondylitis had 
no effect on my 
daily activities 
           Ankylosing 
spondylitis 
completely 
prevented  
me from  
doing my  
daily activities 
0 1 2 3 4 5 6 7 8 9 10 
 
  
Ankylosing 
spondylitis had 
no effect on my 
work 
           Ankylosing 
spondylitis 
completely 
prevented  
me from  
working 
0 1 2 3 4 5 6 7 8 9 10 
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H) MEDICAL SHORT FORM (SF)-36 
 
Questions: 
1. In general, would you say your health is? 
2. Compared to one year ago, how would you rate your health in general now? 
3. The following items are about activities you might do during a typical day. Does 
your health now limit you in these activities? If so, how much? 
a. Vigorous activities, such as running, lifting heavy objects, participating 
in strenuous sports 
b. Moderate activities, such as moving a table, pushing a vacuum cleaner, 
bowling, or playing golf 
c. Lifting or carrying groceries 
d. Climbing several flights of stairs 
e. Climbing one flight of stairs 
f. Bending, kneeling, or stooping 
g. Walking more than a mile 
h. Walking several blocks 
i. Walking one block 
j. Bathing or dressing yourself 
4. During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of your physical health? 
a. Cut down the amount of time you spent on work or other activities. 
b. Accomplished less than you would like 
c. Were limited in the kind of work or other activities 
d. Had difficulty performing the work or other activities (for example, it 
took extra effort) 
5. During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (such 
as feeling depressed or anxious)? 
a. Cut down the amount of time you spent on work or other activities 
b. Accomplished less than you would like 
c. Didn't do work or other activities as carefully as usual 
	 43	
6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbors, or groups? 
7. How much bodily pain have you had during the past 4 weeks? 
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
9. These questions are about how you feel and how things have been with you 
during the past 4 weeks. For each question, please give the one answer that 
comes closest to the way you have been feeling. How much of the time during 
the past 4 weeks 
a. Did you feel full of pep? 
b. Have you been a very nervous person? 
c. Have you felt so down in the dumps that nothing could cheer you up? 
d. Have you felt calm and peaceful? 
e. Did you have a lot or energy? 
f. Have you felt down hearted and blue? 
g. Did you feel worn out? 
h. Have you been a happy person? 
i. Did you feel tired? 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends, relatives, etc.)? 
11. How TRUE or FALSE is each of the following statements for you? 
a. I seem to get sick a little easier than other people 
b. I am as healthy as anybody I know 
c. I expect my health to get worse 
d. My health is excellent 
 
Responses: 
1. Excellent, Very Good, Good, Fair, Poor 
2. Much better now than one year ago, Somewhat better now than one year ago, 
About the same as one year ago, Somewhat worse now than one year ago, Much 
worse than one year ago 
3. Yes, Limited a lot; Yes, Limited a little; No, Not limited at all 
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4. a-d. Yes, No  
5. a-c. Yes, No 
6. Not at all, Slightly, Moderately, Quite a bit, Extremely 
7. None, Very mild, Mild, Moderate, Severe, Very severe 
8. Not at all, A little bit, Moderately, Quite a bit, Extremely 
9. All of the time, Most of the time, A good bit of the time, Some of the time, A 
little of the time, None of the time 
10. All of the time, Most of the time, Some of the time, A little of the time, None 
of the time 
11. Definitely true, Mostly true, Don't know, Mostly false, Definitely false 
 
(Calculations according to: Ware, JE. et al. SF-36 Health Survey Manual 
Interpretations) 
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I) RHEUMATOLOGY INTERNATIONAL: INSTRUCTION FOR AUTHORS 
 
Edited from original to include only instructions relevant to this manuscript. Full 
instructions are available at: 
 
https://www.springer.com/medicine/internal/journal/296?detailsPage=pltci_1060231 
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Abstract 
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Keywords 
Please provide 4 to 6 keywords which can be used for indexing purposes. The keywords 
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submission. 
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Results – Conclusion. In addition, they must coherent and provide main results in 
numbers, not just p-values or interpretations. 
 
Text Formatting 
• Manuscripts should be submitted in Word. 
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• Use the automatic page numbering function to number the pages. 
• Do not use field functions. 
• Use tab stops or other commands for indents, not the space bar. 
• Use the table function, not spreadsheets, to make tables. 
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Headings 
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Abbreviations should be defined at first mention and used consistently thereafter. 
 
Footnotes 
Footnotes can be used to give additional information, which may include the citation 
of a reference included in the reference list. They should not consist solely of a 
reference citation, and they should never include the bibliographic details of a 
reference. They should also not contain any figures or tables. Footnotes to the text are 
numbered consecutively; those to tables should be indicated by superscript lower-case 
letters (or asterisks for significance values and other statistical data). Footnotes to the 
title or the authors of the article are not given reference symbols. Always use footnotes 
instead of endnotes. 
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Important Note on Citation 
Referring to publicized scientific facts and ideas requires proper citations. Citing widely 
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• Tables should always be cited in text in consecutive numerical order. 
• For each table, please supply a table caption (title) explaining the components 
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asterisks for significance values and other statistical data) and included beneath 
the table body. 
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